These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 8621409)

  • 1. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
    Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
    J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
    Hoang AT; Lutterbach B; Lewis BC; Yano T; Chou TY; Barrett JF; Raffeld M; Hann SR; Dang CV
    Mol Cell Biol; 1995 Aug; 15(8):4031-42. PubMed ID: 7623799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
    Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
    Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding and suppression of the Myc transcriptional activation domain by p107.
    Gu W; Bhatia K; Magrath IT; Dang CV; Dalla-Favera R
    Science; 1994 Apr; 264(5156):251-4. PubMed ID: 8146655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
    Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
    Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells.
    Barnouin K; Fredersdorf S; Eddaoudi A; Mittnacht S; Pan LX; Du MQ; Lu X
    Oncogene; 1999 Nov; 18(46):6388-97. PubMed ID: 10597239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
    Gregory MA; Hann SR
    Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
    Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma.
    Gutiérrez MI; Bhatia K; Cherney B; Capello D; Gaidano G; Magrath I
    Ann Oncol; 1997 Oct; 8(10):987-94. PubMed ID: 9402172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes.
    Cinti C; Leoncini L; Nyongo A; Ferrari F; Lazzi S; Bellan C; Vatti R; Zamparelli A; Cevenini G; Tosi GM; Claudio PP; Maraldi NM; Tosi P; Giordano A
    Am J Pathol; 2000 Mar; 156(3):751-60. PubMed ID: 10702389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
    Polack A; Feederle R; Klobeck G; Hörtnagel K
    EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma.
    Hu HM; Arcinas M; Boxer LM
    J Biol Chem; 2002 Mar; 277(12):9819-24. PubMed ID: 11777933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M; Neuberger MS
    Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli.
    Kuttler F; Amé P; Clark H; Haughey C; Mougin C; Cahn JY; Dang CV; Raffeld M; Fest T
    Oncogene; 2001 Sep; 20(42):6084-94. PubMed ID: 11593416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
    Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
    N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
    Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
    Rabbitts TH; Forster A; Hamlyn P; Baer R
    Nature; 1984 Jun 14-20; 309(5969):592-7. PubMed ID: 6547209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
    EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
    Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
    EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles.
    Spencer CA; LeStrange RC; Novak U; Hayward WS; Groudine M
    Genes Dev; 1990 Jan; 4(1):75-88. PubMed ID: 2307371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.